- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Stenotrophomonas.
Displaying page 1 of 1.
EudraCT Number: 2018-001590-24 | Sponsor Protocol Number: 01.01.18 | Start Date*: 2019-03-21 | |||||||||||
Sponsor Name:University of Dundee [...] | |||||||||||||
Full Title: A Trial of the Safety, Tolerability and Efficacy of 2 doses of Cayston (Aztreonam Lysine) compared to placebo in participants with bronchiectasis. | |||||||||||||
Medical condition: Bronchiectasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004208-39 | Sponsor Protocol Number: BAYq3939/15625 | Start Date*: 2013-01-21 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, multicEnter Study comParing CIprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus p... | |||||||||||||
Medical condition: bronchiectasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (Completed) IT (Completed) DK (Completed) FR (Completed) LV (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002327-15 | Sponsor Protocol Number: APHP180596 | Start Date*: 2023-03-15 |
Sponsor Name:APHP | ||
Full Title: Beta-lactam Intermittent versus Continuous infusion and Combination antibiotic therapy in Sepsis | ||
Medical condition: Beta-lactam Intermittent vs Continuous infusion and Combination antibiotic therapy in Sepsis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004659-19 | Sponsor Protocol Number: BAYQ3939/15626 | Start Date*: 2014-04-23 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, multicenter study comparing Ciprofloxacin DPI 32.5 mg BID intermittently administered for 28 days on / 28 days off or 14 days on / 14 days off versus p... | |||||||||||||
Medical condition: non-CF bronchiectasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) LT (Completed) AT (Completed) CZ (Completed) PT (Completed) BG (Completed) LV (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004544-38 | Sponsor Protocol Number: C3601009 | Start Date*: 2020-07-03 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, COMPARATIVE STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF AZTREONAM-AVIBACTAM (ATM-AVI) AND BEST AVAILABLE THERAPY FOR THE TREATMENT OF SERIOUS INF... | |||||||||||||
Medical condition: SERIOUS INFECTIONS DUE TO MULTI-DRUG RESISTANT GRAM- NEGATIVE BACTERIA PRODUCING METALLO-Β-LACTAMASE (MBL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002677-38 | Sponsor Protocol Number: CTX-4430-CF-201 | Start Date*: 2016-02-04 | ||||||||||||||||
Sponsor Name:Celtaxsys Inc. | ||||||||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks... | ||||||||||||||||||
Medical condition: Cystic Fibrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) DE (Completed) IT (Completed) BE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000325-49 | Sponsor Protocol Number: CQBW251B2202 | Start Date*: 2020-04-09 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, subjects and investigator blinded, placebo controlled parallel group study to assess the mode of action of QBW251 in patients with Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Temporarily Halted) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
